(Q38068584)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23253221%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

review article

1 reference

title

Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23253221%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23253221%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Giampaolo Tortora

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23253221%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

Alessandra Felici

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23253221%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Francesco Cognetti

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23253221%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Michele Milella

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23253221%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

publication date

1 December 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23253221%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anticancer Therapy

21 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23253221%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23253221%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23253221%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

1545-1557

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23253221%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Molecular diagnosis and therapy of kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

The genetic basis of kidney cancer: why is tuberous sclerosis complex often overlooked?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Von Hippel-Lindau Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

The Eker rat: establishing a genetic paradigm linking renal cell carcinoma and uterine leiomyoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Lessons from the Eker rat model: from cage to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Hereditary kidney cancer: unique opportunity for disease-based therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Biology of metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Targeted therapeutic strategies for the management of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

mTOR inhibitors in advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Difficulty in predicting survival in metastatic renal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Current treatment considerations in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Targeted therapies for renal cell carcinoma: review of adverse event management strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Optimizing treatment for metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Treating patients with metastatic renal carcinoma: an escape from Phase III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Combination therapy for renal cell cancer: what are possible options?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Treatment selection in metastatic renal cell carcinoma: expert consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Sequential use of targeted agents in the treatment of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Temsirolimus in VEGF-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Resistance to targeted therapy in renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Tumor suppressors and cell metabolism: a recipe for cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Role of insulin, adipocyte hormones, and nutrient-sensing pathways in regulating fuel metabolism and energy homeostasis: a nutritional perspective of diabetes, obesity, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Glucose transport and sensing in the maintenance of glucose homeostasis and metabolic harmony

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

AMPK and cell proliferation--AMPK as a therapeutic target for atherosclerosis and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

An activated mTOR mutant supports growth factor-independent, nutrient-dependent cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Molecular basis for sunitinib efficacy and future clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

Tumor Immunotherapy Directed at PD-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.149

21 January 2018

Identifiers

DOI

10.1586/ERA.12.149

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23253221%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference